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ESGE recommends that individuals with hereditary gastro-
intestinal polyposis syndromes should be surveilled in dedi-
cated units that provide monitoring of compliance and
endoscopic performance measures.
Strong recommendation, moderate quality of evidence,
level of agreement 90%.
ESGE recommends performing esophagogastroduodeno-
scopy, small-bowel examination, and/or colonoscopy earli-
er than the planned surveillance procedure if a patient is
symptomatic.
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Colorectal cancer (CRC) is the fourth most incident cancer and
is the second commonest cause of cancer-related death in Eur-
ope [1]. While the majority of CRC is sporadic, twin studies have
shown that up to 35% of CRC cases have a familial component
[2]. Approximately 2%–5% of CRC cases are genetically deter-
mined by mutations in the adenomatous polyposis coli (APC),
MUTYH, DNA mismatch repair, or other predisposing genes [3].
Although hereditary CRC syndromes are rare, it is of great
importance that clinicians recognize these syndromes so they
can make appropriate management decisions for both the pa-
tient and their family members who may also be at risk. Be-
cause all patients with polyposis syndrome are at high risk of
developing gastrointestinal (GI) malignancies, endoscopic sur-
veillance and interventions are required to prevent the devel-
opment of cancer or to detect cancer at an early stage. Current-
ly, there is uncertainty about the surveillance intervals and op-
timal endoscopic management, and guidelines regarding poly-
posis syndromes are limited. Therefore, the aim of this evi-
dence-based and consensus guideline, commissioned by the
European Society of Gastrointestinal Endoscopy (ESGE), is to
provide clinicians with a comprehensive overview of the man-
agement options regarding endoscopic surveillance and inter-
ventions for the most important polyposis syndromes, namely
familial adenomatous polyposis (FAP), MUTYH-associated poly-
posis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis
syndrome (JPS), and serrated polyposis syndrome (SPS) (over-
view shown in ▶Table 1 [4–28]).
There are several other polyposis-associated genes, includ-
ing PTEN, GREM1, POLE/POLD1, and biallelic NTHL1, that will
not be discussed in this guideline because of their low preval-
ence. A second guideline will focus on the endoscopic manage-
ment of familial and hereditary non-polyposis syndromes.
Methods
The ESGE commissioned this guideline (chair J.v.H.) and ap-
pointed a guideline leader (M.v.L.), who invited the listed au-
thors to participate in the project development. The key ques-
tions were prepared by the coordinating team (M.v.L. and V.R.)
and were then approved by the other members. The coordinat-
ing team formed task force subgroups, each with its own lea-
der, and divided the key topics among these task forces (Ap-
pendix 1 s; see online-only Supplementary Material).
The process of developing the guideline included telephone
conferences, meetings, and online and face-to-face discussions
among the guideline committee members from July 2018 to
June 2019. Searches were performed in MEDLINE, Embase, and
Cochrane. Articles were selected through title and abstract
screening, followed by full-text screening. The results of the
search were presented to all members of the guideline commit-
tee and statements were created by consensus. Evidence levels
and recommendation strengths were assessed using the Grad-
ing of Recommendations Assessment, Development and Evalu-
ation (GRADE) system [29]. Further details on the methodology
of ESGE guideline development have been reported elsewhere
[30].
In May 2019, a draft prepared by M.v.L. and V.R. was sent to
all group members. After the agreement of all group members
had been obtained, the manuscript was reviewed by a member
of the ESGE governing board and an external reviewer, and was
sent for further comments to the ESGE national societies and
individual members. After this, it was submitted to Endoscopy
for publication.
PUBLICATION INFORMATION
This Guideline is an official statement of the European So-
ciety of Gastrointestinal Endoscopy (ESGE). The Grading
of Recommendations Assessment, Development, and
Evaluation (GRADE) system was adopted to define the
strength of recommendations and the quality of evi-
dence.
ABBREVIATIONS
ACG American College of Gastroenterology
AFAP attenuated familial adenomatous polyposis




EMR endoscopic mucosal resection
ESGE European Society of Gastrointestinal Endos-
copy
ESPGHAN European Society for Paediatric Gastroenter-
ology Hepatology and Nutrition
EUS endoscopic ultrasonography
FAP familial adenomatous polyposis
GI gastrointestinal
GRADE Grading of Recommendations Assessment,
Development, and Evaluation
HD high definition
HHT hereditary hemorrhagic telangiectasia
IDUS intraductal ultrasound
JPS juvenile polyposis syndrome
MAP MUTYH-associated polyposis





RCT randomized controlled trial
RR relative risk
SPS serrated polyposis syndrome
VCE video capsule endoscopy
WLE white-light endoscopy

































This guideline was issued in 2019 and will be considered for
update in 2024. Any interim updates will be noted on the ESGE
website: http://www.esge.com/esge-guidelines.html.
As literature on polyposis syndromes is limited, a Delphi pro-
cedure was organized within the guideline committee, consist-
ing of two rounds, in order to gain consensus [31]. All guideline
committee members, except for the research fellow, were
asked to complete the online Delphi questionnaire in isolation,
and responses were anonymized to prevent participants from
influencing each other [32]. In each round, all the guideline
committee members were first asked to rate all the statements
with their level of agreement using a seven-point Likert scale:
“Very strongly agree,” “Strongly agree,” “Agree,” “Neither
agree nor disagree,” Disagree,” “Strongly disagree,” or “Very
strongly disagree” [33]. If the statement was not their area of
expertise, participants had the option to opt out. Secondly, par-
ticipants were asked if the statement was clear and had the op-
portunity to write down their suggestions for improvement.
After the first round of Delphi voting, all statements were dis-
cussed and adjusted if necessary during a face-to-face meeting.
Consensus was reached when ≥80% of the guideline commit-
tee members had voted either “Very strongly agree,” “Strongly
agree,” or “Agree” during the second round of the Delphi pro-
cedure.
1 General recommendations for patients
with a polyposis syndrome














APC 70%–90% 1 in 10000 Classic: > 100 adenomas in colon/
rectum at age 25
100% [4, 5 ,23, 24]
Attenuated: < 100 adenomas





MUTYH 16%–40% 1–4 in
10000
20 –100 adenomas in colon/rec-
tum







80%–94% 1 in 250000 1 ≥2 histologically confirmed
Peutz–Jeghers polyps
2 any number of Peutz–Jeghers
polyps in an individual with a
positive family history of PJS
3 presence of characteristic mu-
cocutaneous pigmentations in an
individual with a positive family
history of PJS
4 any number of Peutz–Jeghers
polyps in an individual with char-
acteristic mucocutaneous pig-
mentation








1 ≥5 juvenile polyps are present
in the colon/rectum or in other
parts of the gastrointestinal tract
2 any number of juvenile polyps
in a patient with one or more















1 ≥5 serrated polyps proximal
to the sigmoid with ≥2 being
>10mm
2 >20 serrated polyps of any size
distributed throughout the colon
15%–30% [14–22]
FIT, fecal immunochemical test; NA, not applicable.
RECOMMENDATION
ESGE recommends that individuals with hereditary gas-
trointestinal polyposis syndromes should be surveilled in
dedicated units that provide monitoring of compliance
and endoscopic performance measures.
Strong recommendation, moderate quality of evidence,
level of agreement 90%.
































Management of patients with polyposis syndrome is challen-
ging. Strict follow-up of these patients with high quality endos-
copy and polypectomy is essential. It has been proven that pro-
vision of healthcare services is more effective when delivered in
an organized and coordinated system [34].
Data from the Danish polyposis registry showed a signifi-
cantly lower CRC risk in call-up cases compared with probands
who were not under surveillance. The tracing and follow-up
program increased life expectancy by 17.0 years [35]. For these
reasons, polyposis patients should be followed in dedicated
units (national registries, genetic counseling centers, or high
risk cancer centers) where endoscopic surveillance recommen-
dations are monitored and audited, in order to improve adher-
ence and provide the highest quality of care.
Surveillance intervals are provided in this guideline, but for
patients with specific complaints, such as anemia, rectal blood
loss, or abdominal pain, endoscopic interventions should be
performed when indicated and not postponed to the next sur-
veillance examination.
▶Table2 and ▶Table 3 provide a summary of all of the
statements, including starting age and interval of endoscopic
surveillance
2 Familial adenomatous polyposis and
MUTYH-associated polyposis
2.1 Background
FAP is caused by an autosomal dominant mutation in the APC
gene [36] (▶Table 1). The disease is characterized by the devel-
opment of up to 100–1000 adenomas throughout the colon
and rectum, and is also associated with extracolonic manifesta-
tions [4]. When the disease is left untreated, the cumulative risk
of developing CRC is 100% at a median age of 35–45 years [4].
Attenuated FAP (AFAP; arbitrarily defined as < 100 adenomas) is
associated with a later onset of CRC and the absolute risk is
thought to be lower than in those with a classical phenotype
(> 100 adenomas) [5]. Duodenal adenomatosis is the most fre-
quent extracolonic manifestation in FAP, and there are no ro-
bust data demonstrating that those with AFAP have a different
duodenal phenotype to those with classical FAP. Approximately
10%–30% of the patients with (attenuated) polyposis pheno-
type will remain without a detectable mutation. In these pa-
tients we suggest they be treated according to their clinical di-
agnosis.
There is no clear cutoff for referring an individual with a his-
tory of colorectal adenomatous polyps for genetic testing. The
guideline of the American College of Gastroenterology advises
referral for individuals with a history of 10 adenomatous polyps
[37]. The Dutch guideline uses 10 or more colorectal adenoma-
tous polyps in patients aged under 60 and 20 or more in those
aged under 70 as a cutoff for referral [38].
The other main adenomatous polyposis syndrome is MAP,
which is caused by a biallelic mutation in the MUTYH gene. Al-
though there is significant phenotypic overlap with FAP, MAP is
often associated with a lower number of colorectal polyps and a
later age of onset, although significant phenotypic variation is
observed [39, 40]. The lifetime risk for CRC in MAP patients
ranges from 19% to 43% [6].
▶ Table 2 Summary table of colonoscopy surveillance statements.
Polyposis syndrome Starting age Surveillance interval Treatment indication
(Attenuated) familial adeno-
matous polyposis
12 –14 years Every 1–2 years Pre- and post-colectomy: remove all
polyps > 5mm
MUTYH-associated polyposis 18 years Every 1–2 years Pre- and post-colectomy: remove all
polyps > 5mm
Peutz–Jeghers syndrome Baseline: 8 years
Routine: 18 years
Baseline: if polyps found, every 1 –3 years
Routine: every 1– 3 years
Elective polypectomy
Juvenile polyposis syndrome 12 –15 years Every 1–3 years Elective polypectomy for polyps > 10mm
Serrated polyposis syndrome NA 1 year: after ≥1 advanced polyp or ≥5 non-
advanced clinically relevant polyps
2 years: after no advanced polyps or < 5 non-
advanced clinically relevant polyps
Clearing/surveillance phase: remove all
polyps ≥5mm and all polyps of any size
with optical suspicion of dysplasia
NA, not applicable.
RECOMMENDATION
ESGE recommends performing esophagogastroduodeno-
scopy, small-bowel examination, and/or colonoscopy ear-
lier than the planned surveillance procedure if a patient is
symptomatic.
Strong recommendation, low quality of evidence, level of
agreement 100%.

































2.2 Colonoscopy surveillance Compared with sporadic cancers, FAP is characterized by ex-
tremely early and multifocal carcinogenesis. However, the ade-
noma–carcinoma sequence is not accelerated, with adenomas
taking up to 15 years to become malignant. Studies in patients
with known APC mutation or clinical polyposis have shown that
the median age of polyp development is 12–17 years [41–45].
In addition, the CRC rate below the age of 20 years is very low,
approximately 1.3% [46].
Data also indicate that the APC mutation site may affect the
severity of disease and cancer development. However, there is a
wide spectrum of colorectal polyp burden in FAP and AFAP and
care needs to be personalized [5]. Therefore, we recommend
starting colonoscopy surveillance at age 12–14 years.
Active endoscopic surveillance is associated with a subse-
quent reduction of CRC incidence and mortality, mostly due to
timely early surgical intervention. Studies showed that 47%–
69% of symptomatic FAP patients were diagnosed with CRC, as
opposed to 2%–4% of relatives with FAP in whom CRC was
found during screening [47, 48].
RECOMMENDATION
ESGE recommends that colonoscopy surveillance in
asymptomatic individuals with familial adenomatous
polyposis should start at the age of 12–14 years.
Strong recommendation, low quality of evidence, level of
agreement 90%.
RECOMMENDATION
ESGE recommends that colonoscopy surveillance of indi-
viduals with familial adenomatous polyposis with an intact
colon should be performed every 1–2 years depending
on the polyp burden.
Strong recommendation, low quality of evidence, level of
agreement 90%.
▶ Table 3 Summary table of gastric and small-bowel surveillance statements.






25 years According to Spigelman
score, adjusted for ap-
pearance of the ampulla
Non-ampullary adenomas: considerer endo-
scopic resection of adenomas ≥10mm
Ampullary adenomas: consider discussing en-
doscopic treatment in a multidisciplinary
setting for adenomas ≥10mm, showing exces-





35 years According to Spigelman
score, adjusted for ap-
pearance of the ampulla
Non-ampullary adenomas: considerer endo-
scopic resection of adenomas≥10mm
Ampullary adenomas: consider discussing en-
doscopic treatment in a multidisciplinary
setting for adenomas ≥10mm, showing exces-







Baseline: if polyps found,
every 1–3 years





8 years Every 1–3 years Elective polypectomy for polyps > 15–20mm,

















NA NA NA NA
MRI, magnetic resonance imaging; NA, not applicable.
































In 16%–40% of the individuals with 20–100 adenomas in
whom FAP was excluded, a MUTYH mutation was found [37].
Furthermore, biallelic MUTYH mutations are found in 7.5% to
12.5% of patients with >100 adenomas in whom a disease-
causing APC mutation is not found [6]. Nieuwenhuis et al. dem-
onstrated that colorectal polyposis was diagnosed at a mean
age of 44.8 years in 254 biallelic MUTYH mutation carriers,
while CRC was diagnosed in 58% of these individuals at an aver-
age age of 48.5 years [49]. Furthermore, these patients had an
11% risk of developing metachronous CRC within 5 years after
surgery, suggesting that biallelic MUTYH mutation carriers may
have accelerated carcinogenesis.
Patients with a monoallelic MUTYH mutation do not develop
adenomatous polyposis. They do however seem to have a
slightly elevated risk of developing CRC compared with the gen-
eral population, although this is not sufficient to warrant en-
hanced surveillance. The management of these individuals
should be the same as for those in the general population [50,
51].
2.3 Management of colorectal neoplasia in patients
with an intact colon
There are no data indicating that endoscopic polypectomy
alone is an appropriate management strategy for patients with
FAP. (Laparoscopic) prophylactic surgery is considered the
standard of care. Most studies reveal a very narrow window be-
tween the diagnosis of colonic polyposis and surgery [43, 45].
However, postponing surgery might be considered based on
overall polyp burden, in particular in those with an attenuated
phenotype. Some patients with mild polyposis may even be
managed endoscopically.
Furthermore, colectomy with ileorectal anastomosis instead
of proctocolectomy with ileo-pouch anal anastomosis can be
considered if the polyp burden in the rectum is relatively lim-
ited (usually < 20 adenomas). The choice of surgery should
take into account a personal or family history of desmoid dis-
ease or a germline mutation predisposing to desmoids [52]. In
addition, prophylactic surgery should be personalized based on
patient preference and after a thorough discussion of the impli-
cations for quality of life and fertility.
Chemoprevention has been proposed as a potential strategy
to reduce polyp burden. Until now, no single chemoprevention
drug has an approved indication for the management of FAP or
MAP [53]. Therefore, endoscopic management and, if neces-
sary, subsequent prophylactic surgery remain the standard of
care.
RECOMMENDATION
ESGE recommends that colonoscopy surveillance of indi-
viduals with MUTYH-associated polyposis with intact co-
lons should be performed every 1–2 years depending on
the polyp burden.
Strong recommendation, low quality of evidence, level of
agreement 90%.
RECOMMENDATION
ESGE suggests that the timing and type of surgery in
individuals with familial adenomatous polyposis/MUTYH-
associated polyposis should be discussed in a multidisci-
plinary setting, thereby taking into account the sex (ferti-
lity), polyp burden, extensiveness of rectal involvement,
personal and family history of desmoid disease, and mu-
tation site in the context of social, personal, and educa-
tional factors.
Weak recommendation, low quality of evidence, level of
agreement 90%.
RECOMMENDATION
ESGE suggests that endoscopic management of colorec-
tal adenomas alone is not recommended in individuals
with familial adenomatous polyposis/MUTYH-associated
polyposis. It may be considered in individuals who have
an attenuated phenotype, provided that high quality sur-
veillance and robust recall systems are in place.
Weak recommendation, low quality of evidence, level of
agreement 60%.
RECOMMENDATION
ESGE suggests that, in individuals with familial adenoma-
tous polyposis/MUTYH-associated polyposis who are not
in need of immediate colectomy and are manageable by
endoscopy, all polyps > 5mm be removed.
Weak recommendation, low quality of evidence, level of
agreement 90%.
RECOMMENDATION
ESGE recommends that colonoscopy surveillance should
start at the age of 18 years in asymptomatic individuals
with MUTYH-associated polyposis.
Strong recommendation, low quality of evidence, level of
agreement 90%.

































2.4 Surveillance and management of colorectal
neoplasia after (procto)colectomy
In FAP patients with total colectomy and ileorectal anasto-
mosis, the incidence of cancer development in the rectal rem-
nant is the biggest concern [54]. The cumulative risk of rectal
cancer varies from 11% to 24% [55–57], while the cumulative
risk of dying from rectal cancer is between 9% and 12.5% [55,
58]. Four independent predictors of progressive rectal disease
have been described: rectal polyp count exceeding 20 or colo-
nic polyp count of 500 or more prior to colectomy, APC muta-
tion at codons 1250–1450, and age less than 25 years at the
time of surgery [57].
In FAP patients with proctocolectomy and ileo-pouch anal
anastomosis, the incidence of cancer in the pouch is lower
than that in the rectal cuff [59]. In a systematic review includ-
ing 92 pouch-related cancers, 23 cancers (25%) developed in
the pouch and 69 (75%) in the anal transitional zone [60]. In a
large series of 206 patients with FAP who underwent proctoco-
lectomy with ileo-pouch anal anastomosis, the risk of develop-
ing adenomas in the pouch was 22% in the mucosectomy with
handsewn anastomosis group, while 51% developed adenomas
in the rectal remnant and/or pouch after stapled ileo-pouch
anal anastomosis (median follow-up 10.3 years) [61]. Other
studies have shown that mucosectomy handsewn anastomosis
is associated with a lower risk of adenomas [59, 62]. Retroflex-
ion in the rectum should always be performed to adequately ex-
plore the anal transitional zone.
Evidence on how to manage polyps in the rectal remnant or
pouch, and the appropriate interval between endoscopies is
scarce. Some experts have shown that, even in severe cases of
rectal polyposis, polyp burden in the rectal remnant can be ef-
fectively reduced by cold snare polypectomies and endoscopic
submucosal resections [63, 64]. One study recommends the
use of argon plasma coagulation, but without evidence of its ef-
fect on cancer prevention [65].
2.5 Duodenal surveillance and management
Individuals with FAP are also at high risk for developing duo-
denal adenomas. In 30%–92% of FAP patients, duodenal ade-
nomas are detected, with a lifetime risk approaching 100%
[66–70]. However, only a minority of patients develop duode-
nal cancer, with a cumulative risk ranging from 4% to 10% by
RECOMMENDATION
ESGE recommends that individuals with familial adeno-
matous polyposis start endoscopic duodenal surveillance
at the age of 25 years.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE suggests duodenal polyps and the ampulla should
be biopsied only if they are not amenable to endoscopic
removal, either because they are too large or because
there is a suspicion of invasive growth.
Weak recommendation, low quality of evidence, level of
agreement 89%.
RECOMMENDATION
ESGE recommends endoscopic removal of all polyps
> 5mm during surveillance of the rectum or pouch in
patients with familial adenomatous polyposis/MUTYH-
associated polyposis.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends all polyps be endoscopically removed
at the anal transitional zone (rectal cuff) after proctoco-
lectomy and ileo-pouch anal anastomosis.
Strong recommendation, low quality of evidence, level of
agreement 89%.
RECOMMENDATION
ESGE recommends thorough inspection and description
of the duodenum and ampullary site at every surveillance
esophagogastroduodenoscopy in individuals with familial
adenomatous polyposis/MUTYH-associated polyposis.
The duodenal surveillance interval should be determined
on the basis of polyp characteristics.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE suggests considering endoscopic resection of non-
ampullary duodenal adenomas≥10mm in patients with
familial adenomatous polyposis/MUTYH-associated poly-
posis.
Weak recommendation, low quality of evidence, level of
agreement 90%.
RECOMMENDATION
ESGE recommends endoscopic surveillance of the rectum
or pouch every 1–2 years in individuals with familial
adenomatous polyposis/MUTYH-associated polyposis de-
pending on the polyp burden.
Strong recommendation, low quality of evidence, level of
agreement 90%.
































the age of 60 [66, 69–73]. The median age at duodenal cancer
diagnosis varied from 52 to 67 years [67, 69,74–76]. Regular
duodenal surveillance and prophylactic surgery has resulted in
a significantly improved prognosis in FAP patients [74].
During esophagogastroduodenoscopy (EGD), the severity of
duodenal polyposis is assessed using the Spigelman classifica-
tion system (▶Table4). Scores for the number, size, histology,
and grade of dysplasia of the duodenal adenomas result in a
Spigelman stage varying from I to IV [77]. Several risk factors
for developing duodenal cancer are acknowledged: age; Spigel-
man stage IV at first endoscopy; duodenal polyps ≥10mm or
containing high grade dysplasia; and ampullary adenomas with
high grade dysplasia, a (tubulo)villous component, or high
grade dysplasia [67, 70, 74–76]. To obtain all components of
the Spigelman score, pathology results are needed; however,
routine biopsies of duodenal polyps may interfere with optical
diagnosis and future endoscopic resection because of fibrosis.
Therefore, taking routine biopsies is currently not recommen-
ded. If endoscopic removal is not necessary because the adeno-
mas are small and there is no suspicion of invasive growth, the
Spigelman stage should be determined based on previous
pathology reports or optical diagnosis to determine the sever-
ity of duodenal polyposis and the surveillance interval. The site
of the ampulla in particular should be evaluated and reported
accurately, as this is a location of preference for adenoma and
cancer development [78].
The surveillance interval should be based both on the Spigel-
man stage and on separate judgment of the ampulla, with sur-
veillance adapted to the shortest interval. For a normal ampul-
la, a surveillance interval of 5 years seems safe; for adenoma-
tous changes in an ampulla < 10mm, a surveillance interval of
3 years; and for an ampulla ≥10mm, a surveillance interval of
1 year is proposed. Cap-assisted endoscopy has been shown to
effectively visualize the ampulla in 95% of FAP patients, avoid-
ing the need for additional side-viewing endoscopy and causing
less burden for the patient [79]. The indications for biopsy need
to be carefully considered and biopsies should not be taken rou-
tinely as biopsies of the ampulla may result in pancreatitis.
Nine widely varying, small single-center studies, including
6–35 patients, described the effect of endoscopic removal of
non-ampullary duodenal adenomas in FAP patients [80–88].
The most frequently reported complications were (intraproce-
dural) bleeding and mild post-procedural abdominal pain [81–
83, 88]. During follow-up, ranging from 18 months to 9.9 years,
one case of duodenal cancer was observed in a patient who had
refused endoscopic surveillance after suffering a severe post-
polypectomy bleed [80, 81,84,87,88]. Recurrence rates at the
resection scar of non-ampullary duodenal adenomas varied
widely from 22% to 100% [84, 85,87,88].
In one study, 35 FAP patients with Spigelman stage IV duo-
denal polyposis were treated with argon plasma coagulation
for small and flat adenomas and endoscopic mucosal resection
(EMR) for sessile and flat adenomas over 10mm [86]. In this
study, Spigelman scores decreased in 95% of the patients. Fur-
thermore, a modeling analysis revealed a 60% decrease in mean
Spigelman score after 150 months [86]. However, Balmforth et
al. showed that downstaging of Spigelman IV patients resulted
in an increased rate of duodenal disease progression compared
with the patients with primary disease progression [89]. Sur-
veillance interval after duodenal polypectomy needs to be de-
termined by the expert endoscopist. There is a lack of data and
a need to better understand the biology of duodenal and am-
pullary adenomas and cancer in order to develop a new system
to stratify cancer risk.
In MAP, the prevalence of duodenal adenomas is lower than
in individuals with FAP, with 17%–34% at a median age of 50
years [90, 91]. Only 6% of these patients with MAP developed
ampullary disease [90]. Because duodenal polyposis occurs la-
ter in life and with a slower progression than in individuals
with FAP, duodenal surveillance may commence at a higher
age. Walton et al. showed that only 8 of 92 MAP patients (9%)
underwent an endoscopic intervention, starting at 38 years
[90]. In this series, two duodenal cancers were diagnosed in
RECOMMENDATION
ESGE recommends starting endoscopic duodenal surveil-
lance in individuals with MUTYH-associated polyposis at
35 years of age.
Strong recommendation, low quality of evidence, level of
agreement 90%.
▶ Table 4 Spigelman Score, adapted from Spigelman et al. [77]. b Re-






0 points 0 5 years
1–4 points I 5 years
5–6 points II 3 years
7–8 points III 1 year
9–12 points IV 6 months, consider (endoscopic or
surgical) treatment
* Additional adjustment based on inspection of the ampullary region.
▶ Table 4 Spigelman Score, adapted from Spigelman et al. [77].
a Points awarded in the calculation of Spigelman score.
Findings at duode-
noscopy




Size, mm 1–4 5–10 >10
Histology* Tubular Tubulovillous Villous
Dysplasia* Low grade NA High grade
* Based on pathology obtained for complete endoscopic removal of duode-
nal polyps or prior pathology results.

































patients with MAP over the age of 60 years who were not under-
going surveillance [90]. Duodenal cancers in MAP patients can
often occur without significant duodenal polyp burden [90, 92].
Duodenal polyps in FAP and MAP often occur in the region of
the ampulla [78]. To prevent ampullary cancer, endoscopic am-
pullectomy can be performed in individuals with adenomatous
changes of the ampulla. However, ampullectomy is associated
with severe complications, therefore benefits and harms
should be weighed in an experienced multidisciplinary setting.
The effect of endoscopic ampullectomy has been evaluated in
three small observational studies, including 8–28 FAP patients
[93–95]. In these series, complication rates such as pancreati-
tis (19%–20%), bleeding (4%–13%), and abdominal pain (8%)
were high [93, 94]. Recurrence at the site of ampullectomy oc-
curred in 0–67% of the cases after a follow-up ranging from 53
to 85 months with no evidence of ampullary cancer [93–95]. In
one study of 15 FAP patients, two (13%) required surgery after
multiple repeated endoscopic resections [93].
Finally, if endoscopic ampullectomy is indicated but not pos-
sible in an expert center, the patient should be referred for sur-
gical intervention.
In the literature, endoscopic ultrasonography (EUS) for the
pretherapeutic staging of ampullary tumors has focused mainly
on advanced ampullary cancers. One study focusing on ampul-
lary adenomas in 38 FAP patients showed no EUS utility, with no
information on duct involvement [93]. A comparison of preo-
perative staging of ampullary tumors showed comparable ac-
curacy of EUS and intraductal ultrasound (IDUS), with an accu-
racy of 63% (EUS) and 78% (IDUS), in particular for advanced
stages [96]. On the other hand, over-staging at EUS/IDUS oc-
curred in 25%–40% of cases of benign adenoma or early can-
cers [96–98]. Therefore, EUS and IDUS present limitations in
the pretherapeutic evaluation of ampullary tumors, with over-
staging of early and even benign lesions.
In patients with FAP, fundic gland polyps are reported in
20%–88% [99, 100]. Fundic gland polyps are thought to have
little tendency for malignant transformation. On the other
hand, gastric adenomas are considered to have a premalignant
potential, given that 8%–14% of gastric adenomas harbor high
grade dysplasia [101, 102]. Historically, the risk of developing
gastric cancer among Western FAP patients was not found to
be higher than the general population [102–104]. However,
two recent series from Western countries, described 17 cases
of gastric cancer, with a median age at diagnosis between 50
and 60 years [102, 103]. In both series, the proximal cancers
were associated with carpeting fundic gland polyposis, which
can make identification of the premalignant adenoma extre-
mely difficult. These findings suggest that identification and re-
section of gastric adenomas are important to prevent the de-
velopment of gastric cancer, but currently there are no data as
to whether or not this is effective.
Two retrospective studies reported that 4%–6% of the FAP
patients had been surgically treated for duodenal polyposis, de-
scribing mortality rates after pancreas-preserving duodenecto-
my ranging from 5% to 33% [105, 106]. The in-hospital morbid-
ity was 49%, without differences between patients with benign
adenomatosis and cancer [106]. After duodenectomy, adeno-
mas occurred in 78% of the FAP patients in the neo-duodenum
after a mean of 46 months, indicating the need for endoscopic
surveillance in these patients [107]. Therefore, it is crucial that
the neo-duodenum is accessible for endoscopic surveillance.
RECOMMENDATION
ESGE recommends that prophylactic duodenectomy in
familial adenomatous polyposis/MUTYH-associated poly-
posis should be reserved for those patients with the
most advanced disease, which cannot be endoscopically
managed.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends performing thorough gastric assess-
ment at the time of duodenal surveillance. If gastric ade-
nomas are suspected, endoscopic resection is recom-
mended, or surgical resection if endoscopically unresect-
able.
Strong recommendation, moderate quality of evidence,
level of agreement 100%.
RECOMMENDATION
ESGE suggests that endoscopic ultrasonography should
not be routinely performed in the pretherapeutic evalua-
tion of ampullary adenomas in individuals with familial
adenomatous polyposis/MUTYH-associated polyposis. It
may be considered for assessment of large or suspicious
ampullas to help exclude invasive growth.
Weak recommendation, low quality of evidence, level of
agreement 89%.
RECOMMENDATION
ESGE suggests treatment for individuals with familial
adenomatous polyposis/MUTYH-associated polyposis
who have ampullary adenomas ≥10mm showing exces-
sive growth or suspicion of invasive growth should be dis-
cussed in a multidisciplinary setting.
Weak recommendations, low quality of evidence, level of
agreement 100%.


































PJS is characterized by the development of hamartomatous
polyps [3]. PJS is diagnosed using clinical criteria (▶Table1) or
by a pathogenic germline mutation in the serine threonine ki-
nase 11 tumor suppressor gene (STK11/LKB1 gene), which is
found in 80%–94% of PJS patients [7]. Individuals with perioral
or buccal pigmentation and/or two or more GI hamartomatous
polyp(s) or a family history of PJS should be referred for genetic
testing [37].
The predominant clinical feature of PJS is GI polyposis, most
often found in the small bowel (60%–90%), where they may
cause bleeding, anemia, and intussusception [108, 109]. The
cumulative risk of GI cancers (excluding pancreatic cancer) has
been reported to be around 33% at the age of 60, increasing to
57% at the age of 70 years [8]. However, data are often histor-
ical, retrospective, and subject to bias that probably overesti-
mates the cancer risk.
Surveillance of the GI tract in PJS patients has two purposes:
(i) to detect GI polyps that may cause complications (bleeding,
anemia, intussusception) and should be removed (in particular
small-bowel polyp-related complications are the predominant
clinical problem) [110, 111]; (ii) to detect cancer (mainly occur-
ring in adults) at an early stage [9].
3.2 Esophagogastroduodenoscopy and colonoscopy
surveillance
Most studies about cancer risk in PJS patients are single-
center cohort studies and rather small, which may overesti-
mate the cancer risk because of ascertainment bias. Giardiello
et al. performed a systematic review including 210 PJS patients
from six studies and reported a cumulative risk of gastric cancer
of 29% at 15–64 years of age, with a relative risk (RR) of 213
(95% confidence interval [CI] 96–368) compared with the gen-
eral population [112]. The average age of gastric cancer diag-
nosis was 30–40 years [9, 113]. The cumulative risk of colon
cancer was 39% at 15–64 years of age, with an RR of 84 (95%
CI 47–137) [113–115].
There are no prospective studies evaluating the effect of sur-
veillance strategies for gastric cancer, duodenal cancer, or CRC.
Furthermore, there is no evidence regarding the type and fre-
quency of surveillance and starting/stopping age. Hamartomas
are predominantly found in the small bowel and colon and only
seldomly give rise to complications in the esophagus or stom-
ach. Latchford et al. evaluated 28 PJS patients who had under-
gone one or more surveillance endoscopies by the age of 18
[111]. In 17 patients a significant gastroduodenal or colonic
polyp was found, including 20 gastroduodenal polyps over
10mm [111]. In this series, no PJS patients were observed to




ESGE recommends small-bowel surveillance from the
age of 8 years in asymptomatic individuals with Peutz–
Jeghers syndrome.
Strong recommendation, moderate quality of evidence,
level of agreement 100%.
RECOMMENDATION
ESGE recommends an interval of 1–3 years based on phe-
notype for small-bowel surveillance.
Strong recommendation, moderate quality of evidence,
level of agreement 100%.
RECOMMENDATION
ESGE recommends a baseline esophagogastroduodeno-
scopy and colonoscopy at the age of 8 years in asympto-
matic individuals with Peutz–Jeghers syndrome.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends an interval of 1–3 years based on phe-
notype for esophagogastroduodenoscopy and colonos-
copy.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends starting routine esophagogastroduo-
denoscopy and colonoscopy surveillance at the age of 18
if the baseline endoscopy is negative.
Strong recommendation, low quality of evidence, level of
agreement 100%. RECOMMENDATION
ESGE recommends either MRI studies or video capsule
enteroscopy for small-bowel surveillance.
Strong recommendation, moderate quality of evidence,
level of agreement 89%.

































Symptoms related to small-bowel polyps are frequent and
intussusception is seen by the age of 10 in 33% and by the age
of 20 in 50% of PJS patients [110]. The cumulative risk of small-
bowel cancer was 13%, with an RR of 520 (95%CI 220–1306)
[113]. The average age of diagnosis of small-bowel cancer was
37–42 years [9, 113]. However, it is difficult to interpret these
data because of the small studies, which may overestimate can-
cer risk due to ascertainment bias, and misinterpretation of
pseudoinvasion as cancer.
Currently, magnetic resonance imaging enteroclysis/entero-
graphy (MRI-E) and video capsule endoscopy (VCE) are the
most used imaging modalities for detection of polyps in the
small bowel [109, 116–119]. There are four studies that have
compared MRI-E and VCE, including a total of 47 patients with
PJS [118–121]. Gupta et al. [118] did not find a significant dif-
ference between the twomodalities for the detection of clinical-
ly relevant polyps (> 10mm), as opposed to Urquhart et al.
[119], who showed superiority for VCE over MRI-E. Both modal-
ities do miss clinically relevant polyps (> 15–20mm or smaller
polyps that do give rise to symptoms). Based on the current lit-
erature, both VCE and MRI-E are reasonable options for small-
bowel surveillance.
3.4 Management of small-bowel polyps
In a cohort study including 110 PJS patients, 69% developed
at least one intussusception at a median age of 16 years [110].
The intussusception occurred in the small bowel in 95% of the
cases. Based on the histology of 37 cases, intussusception oc-
curred owing to polyps with a median diameter of 35mm
(15–60mm). In almost all publications, the indication for bal-
loon endoscopy is set at polyps over 10–15mm on VCE or
MRI-E, although some studies used a threshold of 20mm
[109]. Several studies have shown that polypectomy of relevant
small-bowel polyps can prevent the need for emergency sur-
gery [108, 122, 123].
Balloon-assisted enteroscopy facilitates polypectomy in al-
most all patients with clinically relevant polyps [109]. Single-
balloon and double-balloon enteroscopy (DBE) have been
shown to be effective for the removal of polyps up to 60mm
[124] and 100mm [125], respectively. Prior abdominal surgery
is not a contraindication for balloon enteroscopy. For individ-
uals with too many small-bowel polyps, or large or high risk
polyps, laparoscopically-assisted DBE or intraoperative entero-
scopy can be performed [123].
The effect on cancer reduction is not known. Only one T2N0
adenocarcinoma in the jejunum has been detailed in the DBE
literature, which has reported more than 3000 polypectomies
[109, 111, 126].
4 Juvenile polyposis syndrome
4.1 Background
The diagnosis of JPS is based on clinical criteria [10] (▶Table 1).
Individuals with five or more juvenile polyps in the colorectum
or any juvenile polyps in other parts of the GI tract should un-
dergo genetic testing [37]. A germline mutation in SMAD4 or
BMPR1A is identified in around 40%–60% of those with a clini-
cal diagnosis. Germline mutations in these genes result in two
relatively different phenotypes [127]. SMAD4 mutation carriers
present with colonic and gastric involvement, in combination
with hereditary hemorrhagic telangiectasia (HHT), whereas
BMPR1A mutation carriers mostly develop a colonic phenotype
[11, 12]. JPS is associated with an increased GI cancer risk vary-
ing from 39% to 68% [10, 13].
4.2 Colonoscopy surveillance
RECOMMENDATION
ESGE recommends that elective polypectomy should be
performed for small-bowel polyps > 15–20mm to pre-
vent intussusception. In a symptomatic patient, smaller
polyps causing obstructive symptoms should be re-
moved.
Strong recommendation, low quality of evidence, level of
agreement 90%.
RECOMMENDATION
ESGE recommends device-assisted enteroscopy for the
removal of polyps. Based on phenotype, intraoperative
enteroscopy could be considered.
Strong recommendation, moderate quality of evidence,
level of agreement 89%.
RECOMMENDATION
ESGE recommends that colonoscopy screening in asymp-
tomatic individuals with juvenile polyposis syndrome
starts at the age of 12–15 years.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends an interval of 1–3 years based on phe-
notype for routine colonoscopy surveillance in individuals
with juvenile polyposis.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends that colorectal polyps > 10mm should
be removed in individuals with juvenile polyposis syn-
drome to prevent complications and the development of
colorectal cancer.
Strong recommendation, low quality of evidence, level of
agreement 90%.
































Almost all patients with SMAD4 and BMPR1A germline muta-
tions present with colonic hamartomas, with a wide range of
disease expression from a few polyps to over 100 polyps
[128–130]. Very young patients with symptomatic polyposis
have been reported (4–12 years) [129, 130]. In the largest pub-
lished series of 84 cases fulfilling the clinical criteria for JPS,
from the Johns Hopkins’ hospital, 8 of the 84 patients (9.5%)
developed CRC between the ages of 30 and 58 years, with a life-
time calculated risk of 37% [13]. In another retrospective series
from Baltimore, the frequency of colectomy was 49% [128]. Be-
sides classical cases, a much more severe phenotype has been
described in patients harboring a microdeletion in chromo-
some 10 that involves both the BMPR1A and PTEN genes [131].
4.3 Esophagogastroduodenoscopy surveillance
The lifetime risks of extracolonic cancers, including stom-
ach, pancreas, and small intestine, are difficult to quantify ow-
ing to a lack of good quality data. Risks that have been reported
vary from 20% to 60% [132]. However, these are likely to be in-
fluenced by overestimation of risk due to ascertainment bias.
Gastric cancer has not been reported among patients below
the age of 35 years [128]. However, the majority of SMAD4 mu-
tation carriers develop gastric hamartomas at an early age,
which may progress into a severe diffuse hamartomatous gas-
tritis mimicking Menetrier disease in adulthood [127, 128,
130, 133]. On the other hand, based on limited data, BMPR1A
carriers do not seem to present with gastric involvement [127,
129].
4.4 Small-bowel surveillance
Small-bowel involvement in JPS is rare and, if present, predo-
minantly located in the duodenum [127, 128, 130]. Wain et al.
found a prevalence of 29% for duodenal polyps in SMAD4 muta-
tion carriers [130]. Involvement of the distal duodenum in JPS is
not described [134, 135]. In addition, no cases of jejunal or ileal
carcinoma have been reported. Therefore, EGD seems to be
sufficient for small-bowel surveillance in JPS patients. Finally,
the association of SMAD4 mutation with HHT suggests that, in
expert centers, management of iron deficiency anemia unex-
plained by EGD and colonoscopy could be an indication for
small-bowel evaluation with VCE. In patients with evidence of
HHT, screening for vascular lesions in other organs should be
performed.
5 Serrated polyposis syndrome
5.1 Background
SPS has emerged as the most frequent form of polyposis, with
an estimated prevalence of up to 1:111 (0.9%) of individuals in
fecal occult blood test-based screening cohorts and up to 1:238
(0.42%) in primary screening cohorts [14–17]. SPS is often
grouped with the hereditary polyposis syndromes although no
underlying gene defect has been identified yet. SPS is diag-
nosed using clinical criteria defined by the World Health Orga-
nization criteria, recently revised (▶Table 1) [18, 136].
The prevalence of CRC in patients with SPS has been estima-
ted to range between 15% and 30% and there is an increased
risk for CRC prior to or at the time of SPS diagnosis and treat-
ment [14, 19–22]. In one prospective and three retrospective
cohorts, the cumulative 5-year incidence of CRC under endo-
scopic surveillance ranged between 0 and 7.0% [14, 19, 20,
137].
RECOMMENDATION
ESGE does not recommend small-bowel surveillance in
asymptomatic individuals with juvenile polyposis syn-
drome.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends gastric management (polypectomy,
surgery, surveillance) be discussed in expert multidisci-
plinary teams as no clear algorithm can be proposed
based on the available data.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends that esophagogastroduodenoscopy
surveillance should start at the age of 18 years in asymp-
tomatic individuals with a SMAD4 mutation.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE suggests that esophagogastroduodenoscopy sur-
veillance should start at the age of 25 years in asympto-
matic individuals with a BMPR1A mutation.
Weak recommendation, low quality of evidence, level of
agreement 90%.
RECOMMENDATION
ESGE recommends an interval of 1–3 years depending on
phenotype for esophagogastroduodenoscopy surveil-
lance in individuals with juvenile polyposis syndrome.
Strong recommendation, low quality of evidence, level of
agreement 90%.

































5.2 Colonoscopy surveillance and management of
neoplasia
In SPS patients, successful endoscopic treatment at diagno-
sis (the so-called “clearing phase”) can be achieved in the ma-
jority of patients [14, 20, 138]. However, clearing in some cases
requires commitment, time, and expertise to perform a large
number of polypectomies in one or more procedures [138]. Ac-
cordingly, these patients should be managed in dedicated units
with expert endoscopists in order to prevent unnecessary sur-
gery. Studies with expert endoscopists have shown that EMR
of large serrated lesions is easy, safe, and has a lower recur-
rence rate than for adenomas [139].
The risk of developing CRC during endoscopic surveillance
following diagnosis and clearing of the initial polyp burden
seems to be low. Based on two large retrospective cohort stud-
ies, the cumulative incidence during surveillance varied from 0
to 3.1% after 3–5 years [14, 20]. The median interval between
surveillance colonoscopies in these cohort studies varied be-
tween 12 and 19 months [14, 19–22, 138, 140]. Although the
CRC risk during surveillance is low, one retrospective and one
prospective cohort study reported that the incidence of ad-
vanced neoplasia during surveillance is as high as 34%–42%
after 3 years of surveillance [19, 22].
In a recent study, 271 SPS patients were prospectively fol-
lowed during a median of 3.6 years of surveillance using a per-
sonalized surveillance protocol [141]. Patients were surveilled
at intervals of either 1 or 2 years, depending on their most re-
cent polyp burden and the risk of metachronous advanced neo-
plasia. SPS patients were recommended a surveillance interval
of 1 year if: one or more advanced serrated lesions or adenomas
had been removed; if cumulatively ≥5 relevant polyps (sessile
serrated lesions [irrespective of size], adenomas [irrespective
of size], and/or hyperplastic polyps > 5mm) had been removed;
or if surgery was needed during the last surveillance/clearing
phase. In all other cases, a 2-year surveillance interval was re-
commended. The cumulative CRC and advanced neoplasia inci-
dences after 5 years were 1.3% and 44%, respectively. In the
majority of patients, a 2-year interval was recommended. Fol-
lowing the 2-year protocol, the incidence of advanced neopla-
sia during the next colonoscopy was 16%, compared with 24%
following the shortened 1-year interval (odds ratio [OR] 0.57,
95%CI 0.31–1.07). This evidence suggests that surveillance is
safe, less demanding than the clearing phase, and that surveil-
lance can be extended to 2 years in a large proportion of pa-
tients. During surveillance all polyps ≥5mm and all polyps of
any size with optical suspicion of dysplasia should be removed.
5.3 Advanced imaging in colonoscopy surveillance
Tandem colonoscopy studies have demonstrated that
around 30% of serrated lesions are missed during conventional
colonoscopy, and this is especially relevant in high risk condi-
tions such as SPS [142]. The usefulness of virtual chromoendos-
copy (narrow-band imaging [NBI]) in SPS surveillance has been
assessed in two randomized crossover studies [143, 144]. The
first single-center study included 22 patients and showed lower
polyp miss rates with high definition (HD)-NBI compared with
HD white-light endoscopy (HD-WLE; OR 0.21; 95%CI 0.09–
0.45) [143]. However, in the second multicenter study, com-
parison of the overall polyp miss rates of HD-WLE and NBI
showed no significant difference (P=0.065) [144].
Recently, a multicenter randomized controlled trial (RCT)
evaluated the usefulness of conventional chromoendoscopy
with indigo carmine for the detection of colonic polyps in SPS
[145]. This study demonstrated a significantly higher additional
polyp detection rate in the HD chromoendoscopy group (0.39;
95%CI 0.35–0.44) than in the HD-WLE group (0.22; 95%CI
0.18–0.27; P <0.001). HD chromoendoscopy detected more
serrated lesions (40% vs. 24%; P=0.001), serrated lesions prox-
imal to the sigmoid colon (40% vs. 21%; P=0.001), and serra-
ted lesions > 5mm proximal to the sigmoid colon (37% vs. 18%;
P=0.013) than HD-WLE. Therefore, based on this single RCT the
1 Advanced polyps: (tubulo)villous adenomas, adenomas with high grade
dysplasia, adenomas ≥10mm in diameter, traditional serrated adenomas,
serrated lesions with dysplasia, serrated lesions ≥10mm in diameter.
2 Non-advanced clinically relevant polyps: any adenoma or serrated polyp
that does not meet the criteria for an “advanced polyp,” with the exception
of hyperplastic polyps < 5mm in diameter (which can be left in situ).
RECOMMENDATION
ESGE recommends a surveillance interval of 1 year follow-
ing a colonoscopy with≥1 advanced polyp1 or ≥5 non-
advanced clinically relevant polyps2.
Strong recommendation, low quality of evidence, level of
agreement 80%.
RECOMMENDATION
ESGE recommends a surveillance interval of 2 years in
patients with no advanced polyps1 or < 5 non-advanced
clinically relevant polyps2.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends endoscopic removal of all polyps
≥5mm and all polyps of any size with optical suspicion
of dysplasia in individuals with serrated polyposis syn-
drome before and after entering surveillance.
Strong recommendation, low quality of evidence, level of
agreement 100%.
RECOMMENDATION
ESGE recommends the use of high definition systems in
the endoscopic surveillance of individuals with serrated
polyposis syndrome.
Strong recommendation, moderate quality of evidence,
level of agreement 89%.
































use of conventional chromoendoscopy improves polyp detec-
tion and could be considered in the surveillance of SPS patients.
However, its routine use must be balanced against practical
considerations.
Finally, a recent RCT evaluated the usefulness of Endocuff-
assisted colonoscopy in the surveillance of SPS [146]. In this
study, with 123 SPS patients included, no statistical differences
were found between Endocuff-assisted colonoscopy and HD-
WLE colonoscopy for the detection of overall polyps, serrated
lesions, sessile serrated lesions, and adenomas.
5.4 Screening of first-degree relatives
Most SPS cases seem non-familial. However, the presence of
the disease in family members has been described in previous
reports [137, 147, 148]. Moreover, various studies have de-
scribed an increased incidence of CRC in relatives of patients
with SPS. Boparai et al. investigated the risk of CRC in 347 first-
degree relatives of 57 patients with SPS; they established an ab-
solute risk of CRC of 8% and an RR of 5.4 (95%CI 3.7–7.8)
[149]. Two other studies reported an absolute risk of CRC of
12%–15% in first-degree relatives [150, 151]. The age at diag-
nosis of CRC in relatives ranged from 55 to 62 years in these
studies [148–150]. During follow-up of these first-degree rela-
tives of patients with SPS, retrospective studies [148, 152, 153]
found a high risk of CRC and advanced polyps. Hazewinkel et al.
prospectively investigated the yield of screening colonoscopy in
77 first-degree relatives of patients with SPS in whom no CRC
was found, with significant polyps being present in 43% of pa-
tients [154].
Discussion
The management of patients with polyposis syndromes is chal-
lenging. The various types of polyposis syndrome have variable
risks for a large spectrum of cancers. In addition, the phenotype
may differ among individuals having a specific germline muta-
tion, and even within/between family members carrying the
same mutation. Furthermore, in a proportion of patients with
clinical polyposis, no germline mutation can be identified. This
guideline gives a framework on how these patients should be
endoscopically managed according to the current literature
and expert opinion (▶Table 2 and ▶Table3).
The ESGE aligns with the European Society for Paediatric
Gastroenterology Hepatology and Nutrition (ESPGHAN) guide-
lines on polyposis syndromes in children and young adults
[155–157]. The ESPGHAN guideline differs from this guideline
with regard to the colonoscopy interval for FAP patients with in-
tact colon, with this being 1–3 yearly in the ESPGHAN guideline
and 1–2 yearly in our guideline [156]. We have chosen to align
the FAP and MAP surveillance intervals to make it less confusing
for endoscopists. Again, the interval should mainly be based on
phenotype and the endoscopist may lengthen the surveillance
interval based on adenoma characteristics (number, size, and
degree of dysplasia). The main difference with the American
College of Gastroenterology (ACG) guideline is the proposed
endoscopic management for gastric and duodenal adenomas
in (A)FAP and MAP patients [37]. In contrast with the ACG
guideline, the ESGE guideline does not recommend random
sampling of fundic gland polyps during EGD surveillance. Fur-
thermore, the ESGE advises endoscopic polypectomy of duode-
nal adenomas of ≥10mm.
Disclaimer
The legal disclaimer for ESGE Guidelines [30] applies to the cur-
rent Guideline.
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RECOMMENDATION
ESGE recommends that, for first-degree relatives of indi-
viduals with serrated polyposis syndrome, colorectal can-
cer screening by colonoscopy should be offered from the
age of 45 years.
Strong recommendation, moderate quality of evidence,
level of agreement 80%.
RECOMMENDATION
ESGE recommends that, for first-degree relatives of indi-
viduals with serrated polyposis syndrome, colorectal can-
cer screening by colonoscopy should be offered every 5
years. If polyps are found, surveillance should be based
on polyp characterization.
Strong recommendation, low quality of evidence, level of
agreement 90%.


































E. Dekker was an advisory board chair for Cancer Prevention Pharma-
ceuticals (2019) and is a co-editor for Endoscopy. M. F. Kaminski has
received speaker’s, teaching, and consultancy fees from Olympus
(2017 to present) and speaker’s and teaching fees, and a loan of
equipment from Fujifilm (2019). H. Neuman has provided consultan-
cy services to Fujifilm and Pentax (2012 to present). M. Pellisé has re-
ceived consultancy fees from Norgine Iberia (2019), speaker’s fees
from Casen Recordati (2017–2019), Olympus (2017), and Jansen
(2018), and is a co-editor for Endoscopy; her department has received
an equipment loan from Fujifilm (2017 to present) and a research do-
nation from Fujifilm (2019). J. E. van Hooft has received lecture fees
from Medtronics (2014–2015) and Cook Medical (2019), and consul-
tancy fees from Boston Scientific (2014–2017); her department has
received research grants from Cook Medical (2014–2018) and Ab-
bott (2014–2017).
F. Balaguer, R. Jover, A. Latchford, L. Ricciardiello, V. H. Roos, J.-C.
Saurin, P. J. Tanis, M. E. van Leerdam, A. Wagner have no competing
interests.
References
[1] Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424
[2] Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and
heritable factors in the causation of cancer–analyses of cohorts of
twins from Sweden, Denmark, and Finland. NEJM 2000; 343: 78–85
[3] Jasperson KW, Tuohy TM, Neklason DW et al. Hereditary and familial
colon cancer. Gastroenterology 2010; 138: 2044–2058
[4] Bussey HJR. Familial polyposis coli: family studies, histopathology,
differential diagnosis, and results of treatment. Baltimore: Johns
Hopkins University Press; 1975
[5] Burt RW, Leppert MF, Slattery ML et al. Genetic testing and pheno-
type in a large kindred with attenuated familial adenomatous poly-
posis. Gastroenterology 2004; 127: 444–451
[6] Nielsen M, Morreau H, Vasen HF et al. MUTYH-associated polyposis
(MAP). Crit Rev Oncol Hematol 2011; 79: 1–16
[7] Utsunomiya J, Gocho H, Miyanaga T et al. Peutz-Jeghers syndrome:
its natural course and management. Johns Hopkins Med J 1975; 136:
71–82
[8] Hearle N, Schumacher V, Menko FH et al. Frequency and spectrum of
cancers in the Peutz–Jeghers syndrome. Clin Cancer Res 2006; 12:
3209–3215
[9] van Lier MG, Wagner A, Mathus-Vliegen EM et al. High cancer risk in
Peutz-Jeghers syndrome: a systematic review and surveillance re-
commendations. Am J Gastroenterol 2010; 105: 1258–1264; author
reply 1265
[10] Jass JR, Williams CB, Bussey HJ et al. Juvenile polyposis – a precan-
cerous condition. Histopathology 1988; 13: 619–630
[11] Burt RW, Bishop DT, Lynch HT et al. Risk and surveillance of individ-
uals with heritable factors for colorectal cancer. WHO Collaborating
Centre for the Prevention of Colorectal Cancer. Bull World Health
Organ 1990; 68: 655–665
[12] Chevrel JP, Amouroux J, Gueraud JP. [3 cases of familial juvenile
polyposis]. Chirurgie 1975; 101: 708–721
[13] Brosens LA, van Hattem A, Hylind LM et al. Risk of colorectal cancer
in juvenile polyposis. Gut 2007; 56: 965–967
[14] JE IJ, Rana SA, Atkinson NS et al. Clinical risk factors of colorectal
cancer in patients with serrated polyposis syndrome: a multicentre
cohort analysis. Gut 2017; 66: 278–284
[15] Rivero-Sanchez L, Lopez-Ceron M, Carballal S et al. Reassessment
colonoscopy to diagnose serrated polyposis syndrome in a colorec-
tal cancer screening population. Endoscopy 2017; 49: 44–53
[16] van Herwaarden YJ, Verstegen MH, Dura P et al. Low prevalence of
serrated polyposis syndrome in screening populations: a systematic
review. Endoscopy 2015; 47: 1043–1049
[17] Colussi D, Zagari RM, Morini B et al. Prevalence of serrated polyposis
syndrome in an FIT-based colorectal cancer screening cohort in Italy.
Gut 2017; 66: 1532–1533
[18] Rosty C, Brosens LAA, Dekker E et al. Serrated polyposis. In: WHO
Classification of Tumours Editorial Board Digestive System Tumours.
WHO Classification of Tumours series. 5th edn. Lyon, France: IARC;
2019
[19] Rodriguez-Alcalde D, Carballal S, Moreira L et al. High incidence of
advanced colorectal neoplasia during endoscopic surveillance in
serrated polyposis syndrome. Endoscopy 2019; 51: 142–151
[20] Carballal S, Rodriguez-Alcalde D, Moreira L et al. Colorectal cancer
risk factors in patients with serrated polyposis syndrome: a large
multicentre study. Gut 2016; 65: 1829–1837
[21] Parry S, Burt RW, Win AK et al. Reducing the polyp burden in serra-
ted polyposis by serial colonoscopy: the impact of nationally coor-
dinated community surveillance. N Z Med J 2017; 130: 57–67
[22] Hazewinkel Y, Tytgat KM, van Eeden S et al. Incidence of colonic
neoplasia in patients with serrated polyposis syndrome who under-
go annual endoscopic surveillance. Gastroenterology 2014; 147:
88–95
[23] Bisgaard ML, Fenger K, Bulow S et al. Familial adenomatous polypo-
sis (FAP): frequency, penetrance, and mutation rate. Hum Mutat
1994; 3: 121–125
[24] Rivera B, González S, Sánchez-Tomé E et al. Clinical and genetic
characterization of classical forms of familial adenomatous polypo-
sis: a Spanish population study. Ann Oncol 2010; 22: 903–909
[25] Win AK, Reece JC, Dowty JG et al. Risk of extracolonic cancers for
people with biallelic and monoallelic mutations in MUTYH. Int J Can-
cer 2016; 139: 1557–1563
[26] Lubbe SJ, Di Bernardo MC, Chandler IP et al. Clinical implications of
the colorectal cancer risk associated with MUTYH mutation. J Clin
Oncol 2009; 27: 3975–3980
[27] Aretz S, Stienen D, Uhlhaas S et al. High proportion of large genomic
STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 2005; 26:
513–519
[28] Volikos E, Robinson J, Aittomaki K et al. LKB1 exonic and whole gene
deletions are a common cause of Peutz-Jeghers syndrome. J Med
Genet 2006; 43: e18
[29] Atkins D, Best D, Briss PA et al. Grading quality of evidence and
strength of recommendations. BMJ 2004; 328: 1490
[30] Dumonceau JM, Hassan C, Riphaus A et al. European Society of Gas-
trointestinal Endoscopy (ESGE) Guideline Development Policy.
Endoscopy 2012; 44: 626–629
[31] Linstone HA, Turoff M. The Delphi Method: Techniques and Applica-
tions. Boston: Addison-Wesley Pub. Co; 1975
[32] Jones J, Hunter D. Qualitative Research: Consensus methods for
medical and health services research. BMJ 1995; 311: 376–380
[33] Likert R. A technique for the measurement of attitudes [microform].
1932
[34] Wennberg JE. Time to tackle unwarranted variations in practice. BMJ
2011; 342: d1513
[35] Karstensen JG, Burisch J, Pommergaard HC et al. Colorectal cancer in
individuals with familial adenomatous polyposis, based on analysis
of the Danish Polyposis Registry. Clin Gastroenterol Hepatol 2019:
doi:10.1016/j.cgh.2019.02.008
































[36] Kinzler KW, Nilbert MC, Su LK et al. Identification of FAP locus genes
from chromosome 5q21. Science 1991; 253: 661–665
[37] Syngal S, Brand RE, Church JM et al. ACG clinical guideline: Genetic
testing and management of hereditary gastrointestinal cancer syn-
dromes. Am J Gastroenterol 2015; 110: 223–62; quiz 63
[38] Dutch Society for Clinical Genetics. CBO Guideline Hereditary Colo-
rectal Cancer 2015. Version 2.0. Updated 2015-12-31. Available
from: https://oncoline.nl/erfelijke.darmkanker. Accessed: 17 June
2019
[39] Sutcliffe EG, Bartenbaker Thompson A, Stettner AR et al. Multi-gene
panel testing confirms phenotypic variability in MUTYH-associated
polyposis. Fam Cancer 2019; 18: 203–209
[40] Papp J, Kovacs ME, Matrai Z et al. Contribution of APC and MUTYH
mutations to familial adenomatous polyposis susceptibility in Hun-
gary. Fam Cancer 2016; 15: 85–97
[41] Bulow S. Results of national registration of familial adenomatous
polyposis. Gut 2003; 52: 742–746
[42] Gibbons DC, Sinha A, Phillips RK et al. Colorectal cancer: no longer
the issue in familial adenomatous polyposis? Fam Cancer 2011; 10:
11–20
[43] Booij KA, Mathus-Vliegen EM, Taminiau JA et al. Evaluation of 28
years of surgical treatment of children and young adults with familial
adenomatous polyposis. J Ped Surg 2010; 45: 525–532
[44] Cohen S, Gorodnichenco A, Weiss B et al. Polyposis syndromes in
children and adolescents: a case series data analysis. Eur J Gastroen-
terol Hepatol 2014; 26: 972–977
[45] Kennedy RD, Potter DD, Moir CR et al. The natural history of familial
adenomatous polyposis syndrome: a 24 year review of a single cen-
ter experience in screening, diagnosis, and outcomes. J Ped Surg
2014; 49: 82–86
[46] Vasen HF, Moslein G, Alonso A et al. Guidelines for the clinical man-
agement of familial adenomatous polyposis (FAP). Gut 2008; 57:
704–713
[47] Vasen HF, Griffioen G, Offerhaus GJ et al. The value of screening and
central registration of families with familial adenomatous polyposis.
A study of 82 families in The Netherlands. Dis Colon Rectum 1990;
33: 227–230
[48] Bulow S, Bulow C, Nielsen TF et al. Centralized registration, prophy-
lactic examination, and treatment results in improved prognosis in
familial adenomatous polyposis. Results from the Danish Polyposis
Register. Scand J Gastroenterol 1995; 30: 989–993
[49] Nieuwenhuis MH, Vogt S, Jones N et al. Evidence for accelerated
colorectal adenoma–carcinoma progression in MUTYH-associated
polyposis? Gut 2012; 61: 734–738
[50] Win AK, Dowty JG, Cleary SP et al. Risk of colorectal cancer for car-
riers of mutations in MUTYH, with and without a family history of
cancer. Gastroenterology 2014; 146: 1208–1211.e1–e5
[51] Win AK, Hopper JL, Jenkins MA. Association between monoallelic
MUTYH mutation and colorectal cancer risk: a meta-regression anal-
ysis. Fam Cancer 2011; 10: 1–9
[52] Friedl W, Caspari R, Sengteller M et al. Can APC mutation analysis
contribute to therapeutic decisions in familial adenomatous poly-
posis? Experience from 680 FAP families Gut 2001; 48: 515–521
[53] Ricciardiello L, Ahnen DJ, Lynch PM. Chemoprevention of hereditary
colon cancers: time for new strategies. Nature Rev Gastroenterol
Hepatol 2016; 13: 352–361
[54] Moussata D, Nancey S, Lapalus MG et al. Frequency and severity of
ileal adenomas in familial adenomatous polyposis after colectomy.
Endoscopy 2008; 40: 120–125
[55] Koskenvuo L, Renkonen-Sinisalo L, Jarvinen HJ et al. Risk of cancer
and secondary proctectomy after colectomy and ileorectal anasto-
mosis in familial adenomatous polyposis. Int J Colorectal Dis 2014;
29: 225–30
[56] Sinha A, Tekkis PP, Rashid S et al. Risk factors for secondary proc-
tectomy in patients with familial adenomatous polyposis. Br J Surg
2010; 97: 1710–1715
[57] Church J, Burke C, McGannon E et al. Predicting polyposis severity by
proctoscopy: how reliable is it? Dis Colon Rectum 2001; 44: 1249–
1254
[58] Vasen HF, van Duijvendijk P, Buskens E et al. Decision analysis in the
surgical treatment of patients with familial adenomatous polyposis:
a Dutch-Scandinavian collaborative study including 659 patients.
Gut 2001; 49: 231–235
[59] Friederich P, de Jong AE, Mathus-Vliegen LM et al. Risk of developing
adenomas and carcinomas in the ileal pouch in patients with familial
adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6: 1237–
1242
[60] Smith JC, Schaffer MW, Ballard BR et al. Adenocarcinomas after
prophylactic surgery for familial adenomatous polyposis. J Cancer
Ther 2013; 4: 260–270
[61] von Roon AC, Will OC, Man RF et al. Mucosectomy with handsewn
anastomosis reduces the risk of adenoma formation in the anorectal
segment after restorative proctocolectomy for familial adenoma-
tous polyposis. Ann Surg 2011; 253: 314–317
[62] Zahid A, Kumar S, Koorey D et al. Pouch adenomas in Familial Ade-
nomatous Polyposis after restorative proctocolectomy. Int J Surg
2015; 13: 133–136
[63] Patel NJ, Ponugoti PL, Rex DK. Cold snare polypectomy effectively
reduces polyp burden in familial adenomatous polyposis. Endosc Int
Open 2016; 4: E472– E474
[64] Sansone S, Nakajima T, Saito Y. Endoscopic submucosal dissection of
a large neoplastic lesion at the ileorectal anastomosis in a familial
adenomatous polyposis patient. Dig Endosc 2017; 29: 390–391
[65] Saurin JC, Napoleon B, Gay G et al. Endoscopic management of pa-
tients with familial adenomatous polyposis (FAP) following a colect-
omy. Endoscopy 2005; 37: 499–501
[66] Bjork J, Akerbrant H, Iselius L et al. Periampullary adenomas and
adenocarcinomas in familial adenomatous polyposis: cumulative
risks and APC gene mutations. Gastroenterology 2001; 121: 1127–
1135
[67] Groves CJ, Saunders BP, Spigelman AD et al. Duodenal cancer in pa-
tients with familial adenomatous polyposis (FAP): results of a 10 year
prospective study. Gut 2002; 50: 636–641
[68] Saurin JC, Ligneau B, Ponchon T et al. The influence of mutation site
and age on the severity of duodenal polyposis in patients with fa-
milial adenomatous polyposis. Gastrointest Endosc 2002; 55: 342–
347
[69] Bulow S, Bjork J, Christensen IJ et al. Duodenal adenomatosis in fa-
milial adenomatous polyposis. Gut 2004; 53: 381–386
[70] Sourrouille I, Lefevre JH, Shields C et al. Surveillance of duodenal
polyposis in familial adenomatous polyposis: should the Spigelman
score be modified? Dis Colon Rectum 2017; 60: 1137–1146
[71] Vasen HF, Bulow S, Myrhoj T et al. Decision analysis in the manage-
ment of duodenal adenomatosis in familial adenomatous polyposis.
Gut 1997; 40: 716–719
[72] Wallace MH, Phillips RK. Upper gastrointestinal disease in patients
with familial adenomatous polyposis. Br J Surg 1998; 85: 742–750
[73] Lepisto A, Kiviluoto T, Halttunen J et al. Surveillance and treatment
of duodenal adenomatosis in familial adenomatous polyposis.
Endoscopy 2009; 41: 504–509
[74] Bulow S, Christensen IJ, Hojen H et al. Duodenal surveillance im-
proves the prognosis after duodenal cancer in familial adenomatous
polyposis. Colorectal Dis 2012; 14: 947–952
[75] Latchford AR, Neale KF, Spigelman AD et al. Features of duodenal
cancer in patients with familial adenomatous polyposis. Clin Gas-
troenterol Hepatol 2009; 7: 659–663

































[76] Thiruvengadam SS, Lopez R, O'Malley M et al. Spigelman stage IV
duodenal polyposis does not precede most duodenal cancer cases in
patients with familial adenomatous polyposis. Gastrointest Endosc
2019; 89: 345–354.e2
[77] Spigelman AD, Williams CB, Talbot IC et al. Upper gastrointestinal
cancer in patients with familial adenomatous polyposis. Lancet
1989; 2: 783–785
[78] Kashiwagi H, Spigelman AD, Debinski HS et al. Surveillance of am-
pullary adenomas in familial adenomatous polyposis. Lancet 1994;
344: 1582
[79] Kallenberg FGJ, Bastiaansen BAJ, Dekker E. Cap-assisted forward-
viewing endoscopy to visualize the ampulla of Vater and the duode-
num in patients with familial adenomatous polyposis. Endoscopy
2017; 49: 181–185
[80] Alarcon FJ, Burke CA, Church JM et al. Familial adenomatous poly-
posis: efficacy of endoscopic and surgical treatment for advanced
duodenal adenomas. Dis Colon Rectum 1999; 42: 1533–1536
[81] Cordero-Fernandez C, Garzon-Benavides M, Pizarro-Moreno A et al.
Gastroduodenal involvement in patients with familial adenomatous
polyposis. Prospective study of the nature and evolution of polyps:
evaluation of the treatment and surveillance methods applied. Eur J
Gastroenterol Hepatol 2009; 21: 1161–1167
[82] Hamada K, Takeuchi Y, Ishikawa H et al. Safety of cold snare poly-
pectomy for duodenal adenomas in familial adenomatous polyposis:
a prospective exploratory study. Endoscopy 2018; 50: 511–517
[83] Inoki K, Nakajima T, Nonaka S et al. Feasibility of endoscopic resec-
tion using bipolar snare for nonampullary duodenal tumours in fa-
milial adenomatous polyposis patients. Fam Cancer 2018; 17: 517–
524
[84] Jaganmohan S, Lynch PM, Raju RP et al. Endoscopic management of
duodenal adenomas in familial adenomatous polyposis–a single-
center experience. Dig Dis Sci 2012; 57: 732–737
[85] Morpurgo E, Vitale GC, Galandiuk S et al. Clinical characteristics of
familial adenomatous polyposis and management of duodenal ade-
nomas. J Gastrointest Surg 2004; 8: 559–564
[86] Moussata D, Napoleon B, Lepilliez V et al. Endoscopic treatment of
severe duodenal polyposis as an alternative to surgery for patients
with familial adenomatous polyposis. Gastrointest Endosc 2014; 80:
817–825
[87] Soravia C, Berk T, Haber G et al. Management of advanced duodenal
polyposis in familial adenomatous polyposis. J Gastrointest Surg
1997; 1: 474–478
[88] Yachida T, Nakajima T, Nonaka S et al. Characteristics and clinical
outcomes of duodenal neoplasia in Japanese patients with familial
adenomatous polyposis. J Clin Gastroenterol 2017; 51: 407–411
[89] Balmforth DC, Phillips RK, Clark SK. Advanced duodenal disease in
familial adenomatous polyposis: how frequently should patients be
followed up after successful therapy? Fam Cancer 2012; 11: 553–
557
[90] Walton SJ, Kallenberg FG, Clark SK et al. Frequency and features of
duodenal adenomas in patients with MUTYH-associated polyposis.
Clin Gastroenterol Hepatol 2016; 14: 986–992
[91] Vogt S, Jones N, Christian D et al. Expanded extracolonic tumor
spectrum in MUTYH-associated polyposis. Gastroenterology 2009;
137: 1976–1985.e1–e10
[92] Nielsen M, Poley JW, Verhoef S et al. Duodenal carcinoma in MUTYH-
associated polyposis. J Clin Pathol 2006; 59: 1212–1215
[93] Gluck N, Strul H, Rozner G et al. Endoscopy and EUS are key for ef-
fective surveillance and management of duodenal adenomas in fa-
milial adenomatous polyposis. Gastrointest Endosc 2015; 81: 960–
966
[94] Ma T, Jang EJ, Zukerberg LR et al. Recurrences are common after
endoscopic ampullectomy for adenoma in the familial adenomatous
polyposis (FAP) syndrome. Surg Endosc 2014; 28: 2349–2356
[95] Ouaissi M, Panis Y, Sielezneff I et al. Long-term outcome after am-
pullectomy for ampullary lesions associated with familial adenoma-
tous polyposis. Dis Colon Rectum 2005; 48: 2192–2196
[96] Ito K, Fujita N, Noda Y et al. Preoperative evaluation of ampullary
neoplasm with EUS and transpapillary intraductal US: a prospective
and histopathologically controlled study. Gastrointest Endosc 2007;
66: 740–747
[97] Napoleon B, Gincul R, Ponchon T et al. Endoscopic papillectomy for
early ampullary tumors: long-term results from a large multicenter
prospective study. Endoscopy 2014; 46: 127–134
[98] Menzel J, Hoepffner N, Sulkowski U et al. Polypoid tumors of the
major duodenal papilla: preoperative staging with intraductal US,
EUS, and CT–a prospective, histopathologically controlled study.
Gastrointest Endosc 1999; 49: 349–357
[99] Bianchi LK, Burke CA, Bennett AE et al. Fundic gland polyp dysplasia
is common in familial adenomatous polyposis. Clin Gastroenterol
Hepatol 2008; 6: 180–185
[100] Church JM, McGannon E, Hull-Boiner S et al. Gastroduodenal polyps
in patients with familial adenomatous polyposis. Dis Colon Rectum
1992; 35: 1170–1173
[101] Iida M, Yao T, Itoh H et al. Natural history of gastric adenomas in pa-
tients with familial adenomatosis coli/Gardnerʼs syndrome. Cancer
1988; 61: 605–611
[102] Walton SJ, Frayling IM, Clark SK et al. Gastric tumours in FAP. Fam
Cancer 2017; 16: 363–369
[103] Mankaney G, Leone P, Cruise M et al. Gastric cancer in FAP: a con-
cerning rise in incidence. Fam Cancer 2017; 16: 371–376
[104] Offerhaus GJ, Giardiello FM, Krush AJ et al. The risk of upper gastro-
intestinal cancer in familial adenomatous polyposis. Gastroenterol-
ogy 1992; 102: 1980–1982
[105] Campos FG, Martinez CAR, Bustamante Lopez LA et al. Advanced
duodenal neoplasia and carcinoma in familial adenomatous polypo-
sis: outcomes of surgical management. J Gastrointest Oncol 2017; 8:
877–884
[106] van Heumen BW, Nieuwenhuis MH, van Goor H et al. Surgical man-
agement for advanced duodenal adenomatosis and duodenal cancer
in Dutch patients with familial adenomatous polyposis: a nationwide
retrospective cohort study. Surgery 2012; 151: 681–690
[107] Alderlieste YA, Bastiaansen BA, Mathus-Vliegen EM et al. High rate of
recurrent adenomatosis during endoscopic surveillance after duo-
denectomy in patients with familial adenomatous polyposis. Fam
Cancer 2013; 12: 699–706
[108] Latchford AR, Neale K, Phillips RK et al. Peutz-Jeghers syndrome: in-
triguing suggestion of gastrointestinal cancer prevention from sur-
veillance. Dis Colon Rectum 2011; 54: 1547–1551
[109] Korsse SE, Dewint P, Kuipers EJ et al. Small bowel endoscopy and
Peutz-Jeghers syndrome. Best Pract Res Clin Gastroenterol 2012; 26:
263–278
[110] van Lier MG, Mathus-Vliegen EM, Wagner A et al. High cumulative
risk of intussusception in patients with Peutz–Jeghers syndrome:
time to update surveillance guidelines? Am J Gastroenterol 2011;
106: 940–945
[111] Latchford AR, Phillips RK. Gastrointestinal polyps and cancer in
Peutz-Jeghers syndrome: clinical aspects. Fam Cancer 2011; 10:
455–461
[112] Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of
cancer in familial Peutz–Jeghers syndrome. Gastroenterology 2000;
119: 1447–1453
































[113] Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and manage-
ment recommendations. Clin Gastroenterol Hepatol 2006; 4: 408–
415
[114] Resta N, Pierannunzio D, Lenato GM et al. Cancer risk associated
with STK11/LKB1 germline mutations in Peutz–Jeghers syndrome
patients: results of an Italian multicenter study. Dig Liver Dis 2013;
45: 606–611
[115] Chen HY, Jin XW, Li BR et al. Cancer risk in patients with Peutz–Je-
ghers syndrome: A retrospective cohort study of 336 cases. Tumour
Biol 2017; 39: 1010428317705131
[116] Goverde A, Korsse SE, Wagner A et al. Small-bowel surveillance in
patients with Peutz-Jeghers syndrome: comparing magnetic reso-
nance enteroclysis and double balloon enteroscopy. J Clin Gastro-
enterol 2017; 51: e27– e33
[117] Maccioni F, Al Ansari N, Mazzamurro F et al. Surveillance of patients
affected by Peutz-Jeghers syndrome: diagnostic value of MR enter-
ography in prone and supine position. Abdom Imaging 2012; 37:
279–287
[118] Gupta A, Postgate AJ, Burling D et al. A prospective study of MR en-
terography versus capsule endoscopy for the surveillance of adult
patients with Peutz-Jeghers syndrome. AJR Am J Roentgenol 2010;
195: 108–116
[119] Urquhart P, Grimpen F, Lim GJ et al. Capsule endoscopy versus mag-
netic resonance enterography for the detection of small bowel
polyps in Peutz–Jeghers syndrome. Fam Cancer 2014; 13: 249–255
[120] Schulmann K, Hollerbach S, Kraus K et al. Feasibility and diagnostic
utility of video capsule endoscopy for the detection of small bowel
polyps in patients with hereditary polyposis syndromes. Am J Gas-
troenterol 2005; 100: 27–37
[121] Caspari R, Friedl W, Mandl M et al. Familial adenomatous polyposis:
mutation at codon 1309 and early onset of colon cancer. Lancet
1994; 343: 629–632
[122] Chen TH, Lin WP, Su MY et al. Balloon-assisted enteroscopy with
prophylactic polypectomy for Peutz-Jeghers syndrome: experience
in Taiwan. Dig Dis Sci 2011; 56: 1472–1475
[123] Belsha D, Urs A, Attard T et al. Effectiveness of double-balloon en-
teroscopy-facilitated polypectomy in pediatric patients with Peutz-
Jeghers syndrome. J Ped Gastroenterol Nutr 2017; 65: 500–502
[124] Bizzarri B, Borrelli O, de'Angelis N et al. Management of duodenal-
jejunal polyps in children with Peutz-Jeghers syndrome with single-
balloon enteroscopy. J Ped Gastroenterol Nutr 2014; 59: 49–53
[125] Akarsu M, Ugur KantarF, Akpinar H. Double-balloon endoscopy in
patients with Peutz-Jeghers syndrome. Turkish J Gastroenterol 2012;
23: 496–502
[126] Serrano M, Mao-de-Ferro S, Pinho R et al. Double-balloon entero-
scopy in the management of patients with Peutz-Jeghers syndrome:
a retrospective cohort multicenter study. Rev Esp Enferm Dig 2013;
105: 594–599
[127] Latchford AR, Neale K, Phillips RK et al. Juvenile polyposis syndrome:
a study of genotype, phenotype, and long-term outcome. Dis Colon
Rectum 2012; 55: 1038–1043
[128] Ma C, Giardiello FM, Montgomery EA. Upper tract juvenile polyps in
juvenile polyposis patients: dysplasia and malignancy are associated
with foveolar, intestinal, and pyloric differentiation. Am J Surg Pathol
2014; 38: 1618–1626
[129] Aretz S, Stienen D, Uhlhaas S et al. High proportion of large genomic
deletions and a genotype phenotype update in 80 unrelated families
with juvenile polyposis syndrome. J Med Genet 2007; 44: 702–709
[130] Wain KE, Ellingson MS, McDonald J et al. Appreciating the broad
clinical features of SMAD4 mutation carriers: a multicenter chart re-
view. Genet Med 2014; 16: 588–593
[131] Alimi A, Weeth-Feinstein LA, Stettner A et al. Overlap of juvenile
polyposis syndrome and Cowden syndrome due to de novo chro-
mosome 10 deletion involving BMPR1A and PTEN: implications for
treatment and surveillance. Am J Med Genet A 2015; 167: 1305–
1308
[132] Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carci-
noma in familial juvenile polyposis. Ann Surg Oncol 1998; 5: 751–
756
[133] Gonzalez RS, Adsay V, Graham RP et al. Massive gastric juvenile-type
polyposis: a clinicopathological analysis of 22 cases. Histopathology
2017; 70: 918–928
[134] Jee MJ, Yoon SM, Kim EJ et al. A novel germline mutation in exon 10
of the SMAD4 gene in a familial juvenile polyposis. Gut Liver 2013; 7:
747–751
[135] Postgate AJ, Will OC, Fraser CH et al. Capsule endoscopy for the
small bowel in juvenile polyposis syndrome: a case series. Endoscopy
2009; 41: 1001–1004
[136] Snover DC, Ahnen DJ, Burt RW et al. Serrated polyps of the colon and
rectum and serrated polyposis. In: Bosman T, Carneiro F, Hruban R et
al., eds. WHO classification of tumours of the digestive system.
Lyon, France: IARC; 2010: 160–165
[137] Rubio CA, Stemme S, Jaramillo E et al. Hyperplastic polyposis coli
syndrome and colorectal carcinoma. Endoscopy 2006; 38: 266–270
[138] MacPhail ME, Thygesen SB, Patel N et al. Endoscopic control of polyp
burden and expansion of surveillance intervals in serrated polyposis
syndrome. Gastrointest Endosc 2019; 90: 96–100
[139] Pellise M, Burgess NG, Tutticci N et al. Endoscopic mucosal resection
for large serrated lesions in comparison with adenomas: a prospec-
tive multicentre study of 2000 lesions. Gut 2017; 66: 644–653
[140] Boparai KS, Mathus-Vliegen EM, Koornstra JJ et al. Increased colo-
rectal cancer risk during follow-up in patients with hyperplastic
polyposis syndrome: a multicentre cohort study. Gut 2010; 59:
1094–1100
[141] Bleijenberg AG, IJspeert JE, van Herwaarden YJ et al. Personalised
surveillance for serrated polyposis syndrome: results from a pro-
spective 5-year international cohort study. Gut 2019: doi:10.1136/
gutjnl-2018-318134
[142] Heresbach D, Barrioz T, Lapalus MG et al. Miss rate for colorectal
neoplastic polyps: a prospective multicenter study of back-to-back
video colonoscopies. Endoscopy 2008; 40: 284–290
[143] Boparai KS, van den Broek FJ, van Eeden S et al. Increased polyp de-
tection using narrow band imaging compared with high resolution
endoscopy in patients with hyperplastic polyposis syndrome.
Endoscopy 2011; 43: 676–682
[144] Hazewinkel Y, Tytgat KM, van Leerdam ME et al. Narrow-band ima-
ging for the detection of polyps in patients with serrated polyposis
syndrome: a multicenter, randomized, back-to-back trial. Gastroin-
test Endosc 2015; 81: 531–538
[145] Lopez-Vicente J, Rodriguez-Alcalde D, Hernandez L et al. Panchro-
moendoscopy increases detection of polyps in patients with serra-
ted polyposis syndrome. Clin Gastroenterol Hepatol 2018:
doi:10.1016/j.cgh.2018.10.029
[146] Rivero-Sánchez L, López Vicente J, Hernandez Villalba L et al. Endo-
cuff-assisted colonoscopy for surveillance of serrated polyposis syn-
drome: a multicenter randomized controlled trial. Endoscopy 2019:
doi:10.1055/a-0925-4956
[147] Chow E, Lipton L, Lynch E et al. Hyperplastic polyposis syndrome:
phenotypic presentations and the role of MBD4 and MYH. Gastro-
enterology 2006; 131: 30–39
[148] Lage P, Cravo M, Sousa R et al. Management of Portuguese patients
with hyperplastic polyposis and screening of at-risk first-degree re-
latives: a contribution for future guidelines based on a clinical study.
Am J Gastroenterol 2004; 99: 1779–1784

































[149] Boparai KS, Reitsma JB, Lemmens V et al. Increased colorectal cancer
risk in first-degree relatives of patients with hyperplastic polyposis
syndrome. Gut 2010; 59: 1222–1225
[150] Win AK, Walters RJ, Buchanan DD et al. Cancer risks for relatives of
patients with serrated polyposis. Am J Gastroenterol 2012; 107:
770–778
[151] Egoavil C, Juarez M, Guarinos C et al. Increased risk of colorectal
cancer in patients with multiple serrated polyps and their first-de-
gree relatives. Gastroenterology 2017; 153: 106–112.e2
[152] Caetano AC, Ferreira H, Soares J et al. Phenotypic characterization
and familial risk in hyperplastic polyposis syndrome. Scand J Gastro-
enterol 2013; 48: 1166–1172
[153] Oquinena S, Guerra A, Pueyo A et al. Serrated polyposis: prospective
study of first-degree relatives. Eur J Gastroenterol Hepatol 2013; 25:
28–32
[154] Hazewinkel Y, Koornstra JJ, Boparai KS et al. Yield of screening colo-
noscopy in first-degree relatives of patients with serrated polyposis
syndrome. J Clin Gastroenterol 2015; 49: 407–412
[155] Cohen S, Hyer W, Mas E et al. Management of juvenile polyposis
syndrome in children and adolescents: a position paper from the
ESPGHAN Polyposis Working Group. J Ped Gastroenterol Nutr 2019;
68: 453–462
[156] Hyer W, Cohen S, Attard T et al. Management of familial adenoma-
tous polyposis in children and adolescents: position paper from the
ESPGHAN Polyposis Working Group. J Ped Gastroenterol Nutr 2019;
68: 428–441
[157] Latchford A, Cohen S, Auth M et al. Management of Peutz-Jeghers
syndrome in children and adolescents: a position paper from the
ESPGHAN Polyposis Working Group. J Ped Gastroenterol Nutr 2019;
68: 442–452
van Leerdam Monique E et al. Endoscopic management of polyposis syndromes… Endoscopy 2019; 51: 877–895 895
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ite
it 
Le
id
en
 / 
LU
M
C
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
